Vanguard Group Inc. Has $89.22 Million Stock Holdings in Apogee Therapeutics Inc. $APGE

Vanguard Group Inc. lifted its stake in shares of Apogee Therapeutics Inc. (NASDAQ:APGE) by 6.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,245,631 shares of the company’s stock after purchasing an additional 136,693 shares during the quarter. Vanguard Group Inc. owned 4.87% of Apogee Therapeutics worth $89,219,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Apogee Therapeutics by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after purchasing an additional 694 shares during the period. Millennium Management LLC lifted its holdings in shares of Apogee Therapeutics by 100.0% during the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock worth $9,726,000 after acquiring an additional 130,164 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Apogee Therapeutics by 99.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock worth $33,000 after acquiring an additional 383 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Apogee Therapeutics during the 2nd quarter worth approximately $437,000. Finally, Lisanti Capital Growth LLC bought a new position in Apogee Therapeutics in the second quarter valued at approximately $800,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Apogee Therapeutics Stock Performance

APGE stock opened at $70.92 on Friday. The company has a market capitalization of $4.93 billion, a P/E ratio of -16.81 and a beta of 1.39. The company has a fifty day moving average price of $72.47 and a 200-day moving average price of $60.41. Apogee Therapeutics Inc. has a 52-week low of $26.20 and a 52-week high of $84.56.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.02. As a group, sell-side analysts forecast that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Insider Buying and Selling at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $63.35, for a total value of $1,267,000.00. Following the sale, the chief executive officer directly owned 1,172,987 shares in the company, valued at $74,308,726.45. This represents a 1.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total transaction of $133,525,000.00. Following the sale, the director directly owned 298,647 shares of the company’s stock, valued at $22,786,766.10. This represents a 85.42% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 1,834,200 shares of company stock worth $139,739,253. Insiders own 42.77% of the company’s stock.

Analyst Upgrades and Downgrades

APGE has been the subject of several recent analyst reports. Wolfe Research started coverage on Apogee Therapeutics in a research note on Wednesday, January 7th. They set a “peer perform” rating for the company. Jefferies Financial Group reissued a “buy” rating and issued a $95.00 target price on shares of Apogee Therapeutics in a report on Monday, February 2nd. Deutsche Bank Aktiengesellschaft began coverage on shares of Apogee Therapeutics in a research note on Tuesday, December 9th. They issued a “buy” rating and a $103.00 price target on the stock. BTIG Research set a $137.00 price objective on shares of Apogee Therapeutics in a research report on Tuesday, January 6th. Finally, Royal Bank Of Canada cut their target price on shares of Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating on the stock in a research report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $104.92.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.